Cite

    Bayer, C. et al. (n.d.). Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment. Current opinion in obstetrics and gynecology. 29 (1), p. . [Online].